icad inc.

Greetings and welcome to ICAD Inc. Fourth Quarter and Full Year 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Brian Ritchie, LifeSci Advisors. Please go ahead, sir.

Thank you, operator, and good afternoon, everyone. Joining us today from ICAT are Michael Klein, Chairman and Chief Executive Officer, Stacey Stevens, incoming Chief Executive Officer, and Charles Carter, Chief Financial Officer. Earlier this afternoon, ICAD announced financial results for the three and 12 months ended December 31st, 2021 in a press release, which is also available on the ICAD website. Before we begin, I would like to caution that comments made during this conference call by management contain forward-looking statements, involve risks and uncertainties regarding the operations and future results of ICAD. I would also note that management may refer to certain non-GAAP financial measures. Management believes that these measures provide meaningful information for investors and reflect the way they view the operating performance of the company. You can find a reconciliation of our gap to non-gap measures at the end of the earnings release. I encourage you to review the company's financial filings with the Securities and Exchange Commission, including, without limitation, the forms 10-Q and 10-K. which identifies specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, February 28, 2022. ICAD undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that said, it's my pleasure to turn the call over to Michael Klein. Mike, please go ahead.

Thank you, Brian, and good afternoon, everyone, and thank you for joining us on our fourth quarter and full year update call today. To begin today's call, I would like to remind you of the planned CEO transition we announced in December of last year. I am delighted to welcome Stacey Stevens as ICAD's new Chief Executive Officer, effective tomorrow, March 1st, 2022, at which point I will transition to the primary role of chairman of the board. On behalf of the board, I want to reiterate our support of this world-class management team. It has been a privilege to work closely with Stacey for the past three years, and most especially during this transition period. She brings a relentless focus on leading change and a proven track record of driving growth and innovation. As a company, our focus remains unchanged. We continue to evolve our business and technology, drive sustained market leadership, and aim to create additional significant shareholder value. To this end, we were thrilled to recently appoint two new members to our board of directors, Dana Brown and Timothy Norris Irish, who each offered tremendous insight and decades of relevant experience in corporate leadership, brand stewardship, and health technologies along with proven track records of leading innovation and strategic change. Ms. Brown is currently the Chief Strategy and Operations Officer at Susan G. Komen, the world's leading nonprofit breast cancer organization. She brings over 30 years of industry experience in technology and advocating for improved access to high-quality care, offering direct patient support and empowering people with better solutions to optimize outcomes for patients in an equitable and responsible manner. Timothy Irish is an industry leader with global expertise across the life sciences and healthcare sectors with a foundational understanding of AI-based cancer detection and therapy capabilities that improve patient experience and outcomes. He is currently professor at the Business School at King's College London, a trustee of the Picker Institute Europe, a member of the Alzheimer's Society, as well as several other advisory director or trustee roles to companies in Europe and the United States. He has served as vice chair of the National Institute for Health and Care Excellence, or NICE, otherwise known as NICE, in the United Kingdom, and therefore clearly understands the area of healthcare economics. These appointments offer ICAD a unique and fresh perspective into areas that stand to benefit both from the detection and therapy sides of our business, while also underscoring the company's firm commitments to empowering clinicians and generating better patient care outcomes. In addition to their relationships, in many areas of the global healthcare economy, they are already proving invaluable to ICAT. We remain confident in the clinical and health economic value proposition, our world-leading product portfolio delivers to our customers. And I look forward to continuing to work alongside Stacey and the rest of the management team, as well as the board, as we further advance and grow our business. With that, I will now turn the call over to Stacey to discuss the fourth quarter and provide comments on the current business and market environment.